IMPERATIVE NEED TO IMPROVE OUTCOMES FOR WOMEN DIAGNOSED WITH OVARIAN CANCER. ANZGOG Chair gives stark assessment on late diagnosis, limited treatment options and significantly low survival rates
With
Professor Clare Scott, Chair
Australia New Zealand Gynaecological Oncology Group (ANZGOG) &
Clinician Scientist
WEHI The Walter and Eliza Hall Institute of Medical Research &
Medical Oncologist, Peter MacCallum Cancer Centre, The Royal Women’s Hospital and The Royal Melbourne Hospital
Australian Health Journal Talk
Filmed Online | April 2025
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
ANZGOG’s values—excellence, impact, equity, collaboration, and openness—reflect the organisation’s dedication to transformative cancer research. Its strategic plan is designed around four comprehensive goals, aiming to initiate innovative, practice-changing gynaecological cancer research. This not only expands the reach of impactful studies but also ensures that research directly benefits the community, ultimately improving the lives of countless women affected by these cancers.
Ovarian cancer, a complex and diverse group of diseases, poses significant challenges in diagnosis and treatment. While high-grade serous ovarian cancer is often highlighted, other rare types also demand critical attention. With projections indicating over 1,800 Australian women will be diagnosed by 2025, and a startling survival rate of just under 50%, Professor Scott talks of the need to rally together to confront this pressing public health issue. Tragically, two-thirds of cases are diagnosed at an advanced stage, diminishing survival prospects further. As of now, around 5,300 Australian women live with ovarian cancer, facing ongoing challenges that necessitate urgent action and support.
In this Australian Health Journal Talk, Professor Scott talks in detail about the following –
- The incidence of ovarian cancer in Australian women and mortality statistics around advanced stage diagnosis
- The symptoms and why they get dismissed or misdiagnosed
- The challenges in access to screening, treatment and funding for research
She also delivers a message to the medical community and the Australian Government.
Source: Generative AI on transcript
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
-
Integrated oral health care in midwifery practice
There is limited emphasis being placed on perinatal oral health by prenatal care providers in Australia. Pregnant women have no system in place that can offer them regular oral assessment during pregnancy and prompt dental treatment at minimal or no cost as experienced in other countries. To address the oral health needs of pregnant women, a unique midwifery initiated oral health (MIOH) model was developed to promote and maintain maternal oral health.
-
Reporting on Australian childhood visual impairment: the first 10 years
The Australian Childhood Vision Impairment Register (ACVIR), the first of its kind in Australia, captures uniquely Australian data which is used to improve services for children with vision impairment. The data is also available to researchers who work in the area of eye disease and disorders of vision.
